Jonathan Carapetis — ASN Events

Jonathan Carapetis

The Kids Research Institute Australia, WA, Australia

  • This delegate is presenting an abstract at this event.
Professor Carapetis is the Executive Director of The Kids Research Institute Australia, whose head office is located in Perth, Western Australia. He is an infectious diseases consultant physician at Perth Children’s Hospital, and a Professor at The University of Western Australia. He holds qualifications as a medical practitioner (MBBS), specialist paediatrician (FRACP Paediatrics), specialist infectious diseases physician (FRACP Infect Dis), and specialist public health physician (FAFPHM), as well as a PhD; and is a Fellow of the Australian Academy of Sciences (FAA) and the Australian Academy of Health & Medical Sciences (FAHMS). Professor Carapetis’ previous roles include President of the Association of Australian Medical Research Institutes (AAMRI), Director, Menzies School of Health Research, Darwin; Director, Centre for International Child Health, University of Melbourne; and Theme Director, Murdoch Children's Research Institute, Melbourne. During the COVID-19 pandemic he was a member of the National COVID-19 Health and Research Advisory Committee. Amongst his many accolades, in 2021, Professor Carapetis was awarded an Honorary Doctor of Medicine from Curtin University and received the Professions Award at the 2021 West Australian of the Year Awards. In 2018, he was made a Member of the Order of Australia (AM) for his significant contribution to medical research. In 2013, he was awarded an Honorary Doctor of Science, Charles Darwin University, Northern Territory, and in 2008 he was named Northern Territory Australian of the Year. Professor Carapetis has made an international contribution and commitment to the reduction of rheumatic heart disease and group A streptococcal infections. As Director of the END RHD Centre for Research Excellence, he led the development of the RHD Endgame Strategy: A blueprint to eliminate rheumatic heart disease in Australia by 2031 and, as co-director of the Australian Strep A Vaccine Initiative (ASAVI) and member of the Strep A Vaccine Global Consortium (SAVAC), is at the forefront of global efforts to develop a Strep A vaccine. He has been involved in numerous studies of the burden of vaccine-preventable diseases, and efficacy studies of vaccines in highly endemic settings, including pneumococcal and rotavirus vaccines.
Presentations this author is a contributor to:

Household transmission of Streptococcus pyogenes (Strep A): a review to inform potential environmental health interventions for remote living Aboriginal communities at high risk of rheumatic fever (#274)

5:30 PM
Stephanie Enkel
Poster Session 2

School and clinical-based experimentation to ascertain Streptococcus pyogenes (Strep A)  transmission (#114)

5:30 PM
Stephanie Enkel
Poster Session 1

Group A Streptococcus associated with recurrent tonsillitis form antibiotic-resistant intracellular communities (117312)

2:51 PM
Jua Iwasaki
Concurrent 1a - Microbiology

High rates of group A streptococcal pharyngitis among a longitudinal cohort of school-aged children in remote Western Australia (#143)

5:30 PM
Janessa Pickering
Poster Session 1

Group A Streptococcus molecular point-of-care test performance in remote Australia (#260)

5:30 PM
Janessa Pickering
Poster Session 2

Surveillance of Streptococus pyogenes induced pharyngitis in children from refugee and asylum seeker backgrounds via collaboration with a local health service (#269)

5:30 PM
Ciara Baker
Poster Session 2

Genomic epidemiology of S. pyogenes carriage and pharyngitis isolates from the STAMPS Australian paediatric surveillance study (#155)

5:30 PM
Jasmyn Voss
Poster Session 1

Population pharmacokinetics of penicillin G: insights into increased clearance at low concentrations to guide development of improved long-acting formulations for syphilis and prevention of rheumatic fever (#135)

5:30 PM
Laurens Manning
Poster Session 1

A novel approach to assess antigen specific Fc-mediated antibody functions induced by Streptococcus pyogenes pharyngitis (118113)

4:25 PM
Kaneka Chheng
Plenary 4 - Rapid Fire Session

Identification of a perturbed T cell compartment that underlies rheumatic fever pathogenesis in a trans-Tasman study (118448)

12:20 PM
Francis M Middleton
Plenary 2 - New Insights and New Tools

A randomised, double-blinded, placebo-controlled human challenge trial to establish the lowest penicillin concentration to prevent Streptococcus pyogenes pharyngitis (CHIPS). (118511)

9:39 AM
Laurens Manning
Plenary 5 - Interventions for Prevention

A streptococcal vaccine to prevent cellulitis in older adults (#183)

5:30 PM
Laurens Manning
Poster Session 1

A peptide epitope biomarker signature that differentiates acute rheumatic fever from related clinical presentations (118534)

12:03 PM
Tim Barnett
Plenary 11 - Lancefield Time Machine - The Shape of Things to Come

Comparative analysis of Strep A bacterial detection methods in an Australian paediatric urban pharyngitis surveillance study   (#266)

5:30 PM
Anna Takahashi
Poster Session 2

A plasma protein biomarker signature that differentiates acute rheumatic fever from related clinical presentations (#248)

5:30 PM
Tim Barnett
Poster Session 2

Communication Strategies Used to Maximise Community-Based Participation in the Sore Throat Study in Perth and Melbourne (#283)

5:30 PM
Elizabeth Negus
Poster Session 2

Antibody Responses to Streptococcus pyogenes antigens in an Australian Longitudinal Paediatric Cohort Study (#186)

5:30 PM
Michael Morici
Poster Session 1

The Australian Strep A Vaccine Initiative (ASAVI) Urban Pharyngitis Surveillance Study (#126)

5:30 PM
John Hart
Poster Session 1

Priorities for global control of Strep A (122681)

9:00 AM
Jonathan Carapetis
Plenary 1 - A Global View